戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 imum inactivation (V ), without changing the slope factor.
2 tivation that was accompanied by a change in slope factor.
3 s, defined by half-activation potentials and slope factors.
4  still depend on contentious PEFs and cancer slope factors.
5 dependent inactivation (V1/2 = -41 +/- 2 mV, slope factor = 18 +/- 2 mV, 5 cells).
6              The half-activation voltage and slope factor are -12.5+/-2.6 mV and 7.7+/-1.0 mV, respec
7                                          The slope factors calculated from such fits were 1.2 to 2.1.
8 pplied mixed-effects models, and we computed slope factor, d[PbB]/d[PbA] or the change in PbB per uni
9 arized with an increase in [Ca2+]i while the slope factors decreased.
10 ce calcium-activated potassium channels, the slope factor derived from the Hill equation was signific
11 o 71 +/- 10 (P < 0.01) whereas for K525C the slope factor did not change (18 +/- 2 at baseline and 16
12 ds, display concentration-effect curves with slope factors &gt;1.
13     WT and L529I showed no difference in the slope factor in the absence of NS1643 (8 +/- 0 vs. 9 +/-
14       Both K525C and K525C/K529I had similar slope factors in the absence of NS1643 (18 +/- 2 vs. 34
15 ts with those from the literature shows that slope factor increased with decreasing PbA among childre
16                            The fact that the slope factor is the same between NLC and motility sugges
17 lf-activation potential is V(a)=-52.5mV with slope factor k(a)=16.5mV, whereas for inactivation the c
18 eflected in the midpoint potential (V50) and slope factor (K) of activation.
19                                          The slope factors (k) were -10.1 +/- 1.4, -8.8 +/- 1.4 and -
20 ion (half-maximum potential, V1/2, of -44.5; slope factor, k, of -4.49 mV, means of 3 cells).
21          The Cs(+) conductance-voltage curve slope factor (mean, -4.68 mV; range, -3.63 to -5.72 mV,
22 e error may contribute to the variability in slope factor observed across peer-reviewed studies.
23 etion was fitted by the Hill equation with a slope factor of 2.5 and half-maximal activation at 1.6 m
24 ming lifetime exposure and a proposed cancer slope factor of 25.7 per milligram per kilogram of body
25  steeply voltage dependent, with a Boltzmann slope factor of 5 mV, a midpoint near -45 mV (5 sec cond
26 raged midpoint potential of -94+/-2 mV and a slope factor of 6.9+/-0.1 mV.
27 34 +/- 5, respectively) but with NS1643, the slope factor of K525C/L529I increased from 34 +/- 5 to 7
28 (9 vs. 8) but in the presence of NS1643, the slope factor of K525R was increased to 24 +/- 4 vs. 9 +/
29 red the voltage dependency and the values of slope factor of NLC and somatic motility simultaneously
30                                          The slope factor of the inhibition curve was 1.3.
31      ATP reduced OHC electromotility and the slope factor of the voltage dependence and shifted the o
32 pendent, with half-inactivation voltages and slope factors of -35.1+/-1.3 and -5.4+/-0.4 mV at 37 deg
33 ed at -23.9 and -66.1 mV, respectively, with slope factors of 4.8 and 9.5 mV, respectively.
34    We showed that the voltage dependency and slope factors of NLC and motility were not statistically
35 t activated over the same voltage range with slope factors of their peak conductance-voltage (G-V) re
36 ed only minor changes in the half-points and slope factors of their Q-V relationships.
37 -8.0 mV with a voltage dependence (Boltzmann slope-factor) of 32.7 mV.
38 alues (RfVs) for noncancer effects, and oral slope factors (OSFs) for cancer-that are available for a
39 current characterized by E(rev), V(1/2), and slope factor remained unchanged when co-expressed with S
40                     At baseline, K525R had a slope factor similar to WT (9 vs. 8) but in the presence
41  with an EC(50) value of 1.6 +/- 0.3 microM (slope factor was 1.2 +/- 0.1, n = 4 to 5 cells per conce
42  80-kg adult, and a recently proposed cancer slope factor, we estimated that use of nitarsone by all
43                Using age-specific biokinetic slope factors, we related bioavailable lead from these s

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。